Lipitor Lawsuit News: Bernstein Liebhard Notes Recent Action Taken by Australian Regulators over Lipitor Marketing

The Firm is evaluating Lipitor lawsuits on behalf of individuals who allegedly developed Type 2 diabetes due to their use of Lipitor.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Free Case Review
The action on the part of the ACCC comes as numerous Lipitor lawsuits that allege the drug caused diabetes are moving forward in U.S. courts.

New York, NY (PRWEB) February 13, 2014

As Lipitor lawsuits (http://www.thelipitorlawsuit.com/) continue to mount in the U.S., Bernstein Liebhard LLP notes that Pfizer Inc. is facing additional legal action in Australia over the cholesterol-lowering statin medication. According to a report from Reuters, the Australian Competition and Consumer Commission (ACC) has accused Pfizer of working to deter generic competition by offering pharmacies "significant" discounts and rebates if they stocked at least a year's worth of Lipitor. A complaint filed by the ACC in Sydney federal court on February 13, 2014 alleges that Pfizer engaged in these practices after Lipitor lost patent protection in 2012, Reuters said.*

“The action on the part of the ACCC comes as numerous Lipitor lawsuits that allege the drug caused diabetes are moving forward in U.S. courts. The lawsuits also raise questions about some of the tactics used by Pfizer to market Lipitor,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Lipitor lawsuit consultations to anyone who may have developed Type 2 diabetes due to the use of this statin medication.

Lipitor Diabetes Allegations
Court documents indicate that Pfizer Inc. is facing at least 100 Lipitor lawsuits pending in federal court that allege use of the statin increases the risk that patients will develop Type 2 diabetes. On February 6, 2014, the U.S. Judicial Panel on Multidistrict Litigation (JPML) heard oral arguments regarding a petition filed by a Lipitor plaintiff that seeks the consolidation of all federally-filed claims involving diabetes allegations in a single federal jurisdiction for pretrial proceedings. All of the lawsuits filed against Pfizer thus far claim the company deceptively marketed Lipitor as a safe way to reduce LDL cholesterol levels, even though it was aware for years that the drug was associated with an increased risk of diabetes. Plaintiffs further allege that had they been informed of the link between Lipitor and diabetes, they would never have used the medication. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502 (JPML))

Court records indicate that in April 2013, the JPML had denied a request by plaintiffs to consolidated Lipitor lawsuits. However just around a dozen claims involving diabetes allegations had been filed in federal courts at that time, and the Panel determined that there were too few cases to warrant the creation of a consolidated litigation. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2459 (JPML))

The litigation involving Lipitor and diabetes has been growing since February 2012, when the U.S. Food & Drug Administration (FDA) ordered the manufacturers of statin drugs to add new warnings to their labels regarding their effects on blood sugar levels. According to court documents, plaintiffs in Lipitor lawsuits allege that the new warnings that followed the FDA’s mandate continue to be inadequate.

Alleged victims of Lipitor and diabetes may be entitled to compensation from Pfizer. Find out more about filing a Lipitor lawsuit at Bernstein Liebhard LLP’s website, or call 800-511-5092 to arrange for a free legal review.

*in.reuters.com/article/2014/02/13/pfizer-australia-idINL3N0LI33S20140213, Reuters, February 13, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.thelipitorlawsuit.com/
https://plus.google.com/115936073311125306742?rel=author